The Genetics Society

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

Retrieved on: 
måndag, april 8, 2024
Royal, Medicine, FRS, Biochemical Society, Translational research, Wellcome Sanger Institute, Woman, Drug discovery, Trinity College, Royal Society, International, GSK, University, Membrane, Patient, Doctor of Philosophy, EMBO Gold Medal, University College London, Translation, Architecture, Therapy, Immune system, SAB, The Genetics Society, Molecular biology, Pharmaceutical industry

Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.

Key Points: 
  • Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.
  • During this time, she also collaborated with OMass’ co-founder, Professor Dame Carol Robinson, on unraveling the in vivo and in vitro assembly of soluble protein complexes.
  • Ali Jazayeri, Chief Scientific Officer at OMass Therapeutics, commented: “I look forward to working with Sarah.
  • Our previous long-standing collaboration on the assembly of soluble protein complexes demonstrates how her skillset can be complementary to our native mass spectrometry approach and can contribute to further developing our drug discovery platform.”
    Sarah Teichmann, Member of the Scientific Advisory Board of OMass Therapeutics, added: “I am thrilled to be joining OMass Therapeutics’ SAB.

NTT Research Upgrades Thinking Around Standard Computational Models with Papers on Photonics, Neural Network and More

Retrieved on: 
torsdag, augusti 10, 2023
Research, Technology, Other Technology, Health Technology, Software, Other Health, Health, Data Management, Science, Other Science, Nature Photonics, Society, GSA, Nature Portfolio, SPIE, APS, International conference on Physics of Light–Matter Coupling in Nanostructures, Peer review, Lab, Genetics Society of America, American Association for Cancer Research, College of Engineering (KNUST), OSA, PLMCN, Electronic, Cell Press, IEEE, American Chemical Society, Phi Lab, Publishing, American Association for the Advancement of Science, ACS, American Physical Society, AAAS, Physics, The Genetics Society, PHI, Coherence, Photonics Society of Poland, NTT, Conference, International Society, Advances in Optics and Photonics, Medical imaging, Optica, Neuroscience, Nanostructure

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that its Physics & Informatics (PHI) Lab continues to advance basic scientific knowledge in the areas of neural network, photonics and quantum science.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that its Physics & Informatics (PHI) Lab continues to advance basic scientific knowledge in the areas of neural network, photonics and quantum science.
  • In a three-month span, from March 1 to May 31, ten influential scientific journals published or accepted 12 papers co-authored by PHI Lab scientists.
  • At the same time, members of the PHI Lab delivered 19 talks at six scientific conferences or meetings.
  • “This three-month snapshot indicates the breadth, depth, productivity and impact of our research,” PHI Lab Director Yoshihisa Yamamoto said.

Tracy Johnson and Tom Lister join Cold Spring Harbor Laboratory board

Retrieved on: 
fredag, mars 11, 2022
Biochemistry, Laboratory, Harvard University, SPRING, Genetics Society of America, Cold Spring Harbor Laboratory, Cold, Jet Aviation, Intelsat, Neuroscience, Howard Hughes Medical Institute, Developmental Biology (journal), Education, Cancer, Chemistry, UCLA, Board, Multimedia, Hospital, HSS, Cell, Duke University, Freescale Semiconductor, Hospital for Special Surgery, Forstmann Little & Company, Biomedical Research, List of life sciences, Ruth L. Kirschstein, Division, CSHL, Duff & Phelps, Student, CEO, Nobel Prize, The Genetics Society, Pharmaceutical industry, Management, Trustee, Permira, Genesys

COLD SPRING HARBOR, N.Y., March 11, 2022 /PRNewswire/ -- On March 10, 2022, the Cold Spring Harbor Laboratory (CSHL) Board of Trustees elected two new members to the private, not-for-profit institution's governing body: Tracy L. Johnson, Ph.D., dean, Division of Life Sciences at UCLA; and Tom Lister, senior partner at the international private equity firm Permira.

Key Points: 
  • COLD SPRING HARBOR, N.Y., March 11, 2022 /PRNewswire/ -- On March 10, 2022, the Cold Spring Harbor Laboratory (CSHL) Board of Trustees elected two new members to the private, not-for-profit institution's governing body: Tracy L. Johnson, Ph.D., dean, Division of Life Sciences at UCLA; and Tom Lister, senior partner at the international private equity firm Permira.
  • "Tom Lister will share valuable experience from the finance sector and insights from his service as a trustee in the healthcare sector."
  • Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology.
  • Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians.

CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors

Retrieved on: 
måndag, oktober 4, 2021
UCSF, Therapy, Medicine, Â, Susan, BRCA2, Royal Society, University, Cancer Research UK, SAN, Safety, Tumor microenvironment, Breast cancer, PARP, Academy, Technology, Biotechnology, Research, Academy of Medical Sciences (United Kingdom), LinkedIn, CD166, Twitter, Bristol Myers Squibb, Royal, Imperial College London, FRS, European Molecular Biology Organization, United, Biochemistry, Clinical trial, Breast, Neoplasm, Oncology, Samuel, Cancer, Institute, The Genetics Society, Toxicity, Company, European Society for Medical Oncology, Risk, University College London, Drug discovery, GLOBE, University of California, ADP, CD71, Doctor of Philosophy, Patient, University of London, Chemistry, COVID-19, AbbVie, Nasdaq, Meyenburg, Pharmaceutical industry, Management

It is a privilege to welcome Alan to our board, commented Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics.

Key Points: 
  • It is a privilege to welcome Alan to our board, commented Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics.
  • It is my pleasure to join CytomXs board as the Company continues to innovate and advance its broad and diverse pipeline of potential first-in-class product candidates, said Dr. Ashworth.
  • I look forward to working with the entire board and the executive team to help advance CytomXs vision of bringing more effective therapies to cancer patients.
  • For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter .